



05 November 2024

**Our Ref:** FOI 182

Dear

**Freedom of Information Act 2000  
Information in Relation to Breast Cancer Treatment**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to above which you requested on 9 October 2024.

A response to each of the questions raised has been provided by the Medicine, Unscheduled Care & Cancer Services Directorate and is attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital ([informationgovernance@setrust.hscni.net](mailto:informationgovernance@setrust.hscni.net)) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

---

**Rebecca Manning**  
**Information Governance Officer**

**Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies, listed in table 1?**

A1. Please see Table 1\* for the number of patients treated with the listed therapies, in the past 3 months.

Table 1

Treatment	No. of Patients Treated
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	7
Abemaciclib + Fulvestrant	Nil
Alpelisib + Fulvestrant	Nil
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	Nil
Aromatase Inhibitor as a single agent	Nil
Atezolizumab	<5
Capecitabine as a single agent	9
Carboplatin + Paclitaxel	Nil
Eribulin as a single agent or in combination	5
Everolimus + Exemestane	Nil
Fulvestrant as a single agent	8
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	11
Palbociclib + Fulvestrant	7
Parp Inhibitors (Olaparib/Talazoparib)	Nil
Pembrolizumab	5
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	11
Ribociclib + Fulvestrant	Nil
Sacituzumab Govitecan	<5
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	Nil
Transtuzumab deruxtecan	Nil
Trastuzumab as a single agent or in combination	Nil
Trastuzumab emtansine	Nil
Any other active systemic anti-cancer therapy	73

\*Please note that where numbers in Table 1 & 2 are 1-4, in line with Trust policy, it is given as <5, to reduce any risk of identification of individual patients.

**Q2. Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.**

A2. Yes, the Trust participates in clinical trial for breast cancer, please see Table 2\* for the trial names and number of patients taking part.

Table 2

<b>Study/Trial</b>	<b>No. of Patients Enrolled</b>
Optima	5
Horizons	148
Poetic	20
Loris	<5